This subject belongs in our "studies" section, but because of its importance I included it here as well as in the "introduction" section of the forum.
"
Early treatment with hydroxychloroquine: a country-based analysisCovid Analysis, August 5, 2020 (updated September 6, 2020)"
"Many countries either adopted or declined early treatment with HCQ,
effectively forming a large trial with 1.8 billion people in the treatment group and 663 million in the control group. As of September 15, 2020, an average of 65.1 per million in the treatment group have died, and 471.8 per million in the control group, relative risk 0.138. After adjustments, treatment and control deaths become 136.2 per million and 704.7 per million, relative risk 0.19. The probability of an equal or lower relative risk occurring from random group assignments is 0.013. Accounting for predicted changes in spread, we estimate a relative risk of 0.25.
The treatment group has a 74.8% lower death rate. Confounding factors affect this estimate. We examined diabetes, obesity, hypertension, life expectancy, population density, urbanization, testing level, and intervention level, which do not account for the effect observed."
https://hcqtrial.com/I wondered why Costa Rica seemed to be running off the rails and found this: "
Costa Rica Suspends Use of Hydroxychloroquine to Treat COVID-19 Patients"
https://hcqtrial.com/Particularly the EARLY OUTpatient studies, most relevant to hydroxychloroquine's performance.
https://c19study.com/#earlyWhy do poor African countries have less than 1% of the COVID death rate that some "developed" western countries do?https://www.bitchute.com/video/xR4druFBssHd/
